Outcomes17

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 17 of 17

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Change in Excess Central Macular Thickening in the Study Eye, as Measured by Optical Coherence Tomography (OCT), at Week One Compared to Baseline	Baseline and 1 Week	µm	MEAN
SECONDARY	Change in Excess Central Macular Thickening in the Fellow Eye, as Measured by Optical Coherence Tomography (OCT), at Week One Compared to Baseline	Baseline and 1 Week	µm	MEAN
SECONDARY	Change in Excess Central Macular Thickening in the Study Eye, as Measured by Optical Coherence Tomography (OCT), at Week Two Compared to Baseline	Baseline and 2 Weeks	µm	MEAN
SECONDARY	Change in Excess Central Macular Thickening in the Fellow Eye, as Measured by Optical Coherence Tomography (OCT), at Week Two Compared to Baseline	Baseline and 2 Weeks	µm	MEAN
SECONDARY	Change in Macular Volume in the Study Eye, as Measured by Optical Coherence Tomography (OCT), at Week One Compared to Baseline	Baseline and 1 Week	mm^3	MEAN
SECONDARY	Change in Macular Volume in the Fellow Eye, as Measured by Optical Coherence Tomography (OCT), at Week One Compared to Baseline	Baseline and 1 Week	mm^3	MEAN
SECONDARY	Change in Macular Volume in the Study Eye, as Measured by Optical Coherence Tomography (OCT), at Week Two Compared to Baseline	Baseline and 2 Weeks	mm^3	MEAN
SECONDARY	Change in Macular Volume in the Fellow Eye, as Measured by Optical Coherence Tomography (OCT), at Week Two Compared to Baseline	Baseline and 2 Weeks	mm^3	MEAN
SECONDARY	Change in ETDRS Best-corrected Visual Acuity (BCVA) in the Study Eye at Week One Compared to Baseline	Baseline and 1 Week	ETDRS Letters	MEAN
SECONDARY	Change in ETDRS Best-corrected Visual Acuity (BCVA) in the Fellow Eye at Week One Compared to Baseline	Baseline and 1 Week	ETDRS Letters	MEAN
SECONDARY	Change in ETDRS Best-corrected Visual Acuity (BCVA) in the Study Eye at Week Two Compared to Baseline	Baseline and 2 Weeks	ETDRS Letters	MEAN
SECONDARY	Change in ETDRS Best-corrected Visual Acuity (BCVA) in the Fellow Eye at Week Two Compared to Baseline	Baseline and 2 Weeks	ETDRS Letters	MEAN
SECONDARY	Change in Intraocular Pressure (IOP) in the Study Eye at Week One Compared to Baseline	Baseline and 1 Week	mm Hg	MEAN
SECONDARY	Change in Intraocular Pressure (IOP) in the Fellow Eye at Week One Compared to Baseline	Baseline and 1 Week	mm Hg	MEAN
SECONDARY	Change in Intraocular Pressure (IOP) in the Study Eye at Week Two Compared to Baseline	Baseline and 2 Weeks	mm Hg	MEAN
SECONDARY	Change in Intraocular Pressure (IOP) in the Fellow Eye at Week Two Compared to Baseline	Baseline and 2 Weeks	mm Hg	MEAN
SECONDARY	Proportion of Participants With a Visual Loss of 15 or More Early Treatment Diabetic Retinopathy Study (ETDRS) Letters in the Study Eye	Baseline and 2 Weeks	Percentage of Participants	NUMBER

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01376362/outcomes

API reference For AI assistants